Targeting Iron in Colon Cancer via Glycoconjugation of Thiosemicarbazone Prochelators
- 详细技术说明
- Title: Targeting Iron in Colon Cancer Via Glycoconjugation of Thiosemicarbazone Prochelators Invention: The invention is a novel strategy to create iron chelators by utilizing a disulfide redox switch to connect carbohydrate moieties to a thiosemicarbazone iron-binding unit. This increases expression of glucose transporters in colorectal cancer cells and greater toxicity to cancer cells. Background: An increased amount of iron in colorectal cancer cells is a general characteristic of malignancy, and higher expression of glucose transporter is related to poorer prognosis. Iron chelators are currently marred with poor selectivity and resulting systematic toxicity as well as side effects. Applications: Drug companiesBiotechnology companiesDiagnostic assay companies Advantages:Provides a novel pathway for pharmaceutical companies to treat colorectal cancerProvides greater selectivity and toxicity towards target cancer cellsProvides greater water solubility Licensing Manager:Laura SilvaLauraS@tla.arizona.edu(520) 626-1557
- *Abstract
-
None
- *Principal Investigation
-
Name: Elisa Tomat, Assistant Professor
Department: Chemistry & Biochemistry
Name: Eman Akam, Graduate Assistant
Department: Chemistry
- 国家/地区
- 美国
欲了解更多信息，请点击 这里
